Inflammatory Mechanisms and Oxidative Stress in Peyronies Disease: Therapeutic “Rationale” and Related Emerging Treatment Strategies
The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Abstract
Peyronie's disease (PD) is a connective tissue disorder characterized by a fibrous plaque involving the tunica albuginea of the penis. The inelastic fibrous plaque leads to a penile curvature. Several Authors have suggested an immunological genesis of this disease, others have linked PD with Dupuytren's contracture. Signs of this disease are curvature, penile pain, penile deformity, difficulty with coitus, shortening, hinging, narrowing and erectile dysfunction. The natural history of PD and the clinical course can develop from spontaneous resolution of symptoms to progressive penile deformity and impotence. Surgical treatment is indicated when patients fail the conservative medical treatment and however, only in case of disease stabilization with a condition of impossibility of penetration. The medical treatment is indicated in the development stage of PD for at least one year after diagnosis and whenever in case of penile pain. Current non-surgical therapy includes vitamin-E, verapamil, para-aminobenzoate, propoleum, colchicine, carnitine, tamoxifen, interferons, collagenase, hyaluronidase, cortisone, pentoxifylline, superoxide dismutase, iontophoresis, radiation, extracorporeal shock wave therapy (ESWT) and the penile extender. The etiology of this fibrotic disease is not widely known, although in recent years pathophysiological knowledge has evolved and new studies propose the penile trauma as cause of the disease. The penile trauma results in a delamination of the tunica albuginea with a consequent small hematoma, then the process evolves as an inflammation with accumulation of inflammatory cells and production of reactive oxygen species (ROS). In the course of the inflammation, Peyronie's disease occurs due to the activation of nuclear factor kappa-B, that induces the production of inducible nitric oxide synthase (iNOS), with an increase of nitric oxide, leading to increased production of peroxynitrite anion. All these processes result in the proliferation of fibroblasts and myo-fibroblasts and excessive production of collagen between the layers of the tunica albuginea (penile plaque). Referring to the current knowledge of inflammatory and oxidative mechanisms of PD, a possible therapeutic strategy is then analyzed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At the same time, increased oxidative stress results in the production of reactive oxygen species, which causes cellular damage and worsens the fibrotic process.”
From Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. (2024) · cites this paper as [89]
In the citing paper
“Combination therapies may be a promising approach to enhance the effectiveness of treatment for PD.”
From Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. (2024) · cites this paper as [89]
In the citing paper
“By combining drugs that target different signaling pathways or disease processes, a more comprehensive therapeutic effect can be achieved, addressing multiple aspects of the disease progression.38,48,89,122”
From Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. (2024) · cites this paper as [89]
In the citing paper
“PD progresses in two main stages. The first phase typically lasts between 12 and 18 months; this phase is the “active inflammatory phase”, in which plaque forms and progresses to fibrosis and potential calcification, accompanied by pain and worsening of the penile deformity. In the second phase, known as the chronic “stabilized phase”, penile pain decreases and the plaque size and deformity stabil”
From Clinical Presentation of Peyronie’s Disease: A Retrospective Study of 564 Cases (2024) · cites this paper as [19]
In the citing paper
“In the scientific literature, several articles have appeared in the 21st century that have clarified the important role that “oxidative stress” plays in the pathophysiology of PD [15,16,17,18,19,20,21,22].”
From Clinical Presentation of Peyronie’s Disease: A Retrospective Study of 564 Cases (2024) · cites this paper as [19]
Citations
Cites
1 retracted
Safarinejad, M. R., Asgari, M. A., Hosseini, S. Y., & Dadkhah, F. (2010) · BJU International · doi:10.1111/j.1464-410x.2009.09041.x · Cited by 77 · cited 1×
“A double-blind placebo-controlled study in men with PD, has shown that PTX (400 mg/ oral / twice daily / 6 months) was moderately effective in reducing penile curvature and plaque size [88]; however the results were statistically significant.”
BackgroundRetractedNatarajan, K., Singh, S., Burke, T. R., Grunberger, D., & Aggarwal, B. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9090 · Cited by 1,139 · cited 1×
“Propolis, mainly due to its component CAPE, inhibits NF- B activity and the production of interleukins [78-80].”
BackgroundThe Natural History of Peyronie’s Disease
Gelbard, M. K., Dorey, F., & James, K. (1990) · Journal of Urology · doi:10.1016/s0022-5347(17)39746-x · Cited by 525
STRYKER, W. S., KAPLAN, L. A., STEIN, E. A., STAMPFER, M. J., SOBER, A., & WILLETT, W. C. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114804 · Cited by 521 · cited 1×
“We believe that the discovery of this association is due to the well-known adverse effects of cigarette smoking on the antioxidant defense system [15-18].”
BackgroundLi, Y., Foster, W., Deasy, B. M., Chan, Y., Prisk, V., Tang, Y., Cummins, J., & Huard, J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63188-4 · Cited by 451
The prevalence of Peyronie's disease: results of a large survey
Schwarzer, U., Sommer, F., Klotz, T., Braun, M., Reifenrath, B., & Engelmann, U. (2001) · BJU International · doi:10.1046/j.1464-4096.2001.02436.x · Cited by 440
An Analysis of the Natural History of Peyronie’s Disease
Mulhall, J. P., Schiff, J., & Guhring, P. (2006) · Journal of Urology · doi:10.1016/s0022-5347(06)00270-9 · Cited by 417 · cited 1×
“Though some studies reported the spontaneous resolution in patients without any therapy [23, 24], other authors have achieved a worsening of the penile curvature, respectively, in 30,2% and 48% of cases at follow-up [25, 26].”
ResultMULHALL, J. P., CREECH, S. D., BOORJIAN, S. A., GHALY, S., KIM, E. D., MOTY, A., DAVIS, R., & HELLSTROM, W. (2004) · Journal of Urology · doi:10.1097/01.ju.0000127744.18878.f1 · Cited by 385
Karlsen, A., Retterstøl, L., Laake, P., Paur, I., Kjølsrud-Bøhn, S., Sandvik, L., & Blomhoff, R. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.8.1951 · Cited by 384 · cited 1×
“Blueberry anthocyanins (flavonoids) inhibit NF- B, iNOS and COX-2 expression [116, 117].”
BackgroundProposal: Trauma as the Cause of the Peyronie's Lesion
Devine, C. J. J., Somers, K. D., Jordan, G. H., & Schlossberg, S. M. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65361-8 · Cited by 381 · cited 1×
“The etiology of this fibrotic disease is not widely known, although in recent years pathophysiological knowledge has evolved and new studies propose the penile trauma (micro- or macro-trauma) as cause of the disease [19,20].”
BackgroundThe influence of cigarette smoking on circulating concentrations of antioxidant micronutrients
Alberg, A. J. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00386-4 · Cited by 349 · cited 1×
“We believe that the discovery of this association is due to the well-known adverse effects of cigarette smoking on the antioxidant defense system [15-18].”
BackgroundEffect of flavonoids and Vitamin E on cyclooxygenase-2 (COX-2) transcription
O’Leary, K. A., Pascual-Tereasa, S. D., Needs, P. W., Bao, Y.-P., O’Brien, N. M., & Williamson, G. (2004) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.01.015 · Cited by 330 · cited 1×
“It was found that Vitamin E and its metabolites have an antiinflammatory and anti-cyclooxygenase-2 (COX-2) property [74,75].”
BackgroundXiao, X., Shi, D., Liu, L., Wang, J., Xie, X., Kang, T., & Deng, W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022934 · Cited by 269 · cited 2×
“I ROS release of cytokines NF-kB activation NO iNOS ( superoxide anion ) O2-.”
BackgroundDietrich, M., Block, G., Norkus, E. P., Hudes, M., Traber, M. G., Cross, C. E., & Packer, L. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.1.160 · Cited by 243 · cited 1×
“We believe that the discovery of this association is due to the well-known adverse effects of cigarette smoking on the antioxidant defense system [15-18].”
BackgroundThe Anatomy of the Tunica Albuginea in the Normal Penis and Peyronie's Disease
Brock, G., Hsu, G.-L., Nunes, L., von Heyden, B., & Lue, T. F. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65359-x · Cited by 226 · cited 1×
“The albuginea of the corpora cavernosa consists of two layers of connettive tissue (outer longitudinal and inner circular layer) [1].”
BackgroundHellstrom, W. J. G., Kendirci, M., Matern, R., Cockerham, Y., Myers, L., Sikka, S. C., Venable, D., Honig, S., McCullough, A., Hakim, L. S., et al. (2006) · Journal of Urology · doi:10.1016/s0022-5347(06)00517-9 · Cited by 223 · cited 2×
“In most of studies interferon alfa-2a (IFN- -2b) was used (intralesional injection) [66, 67]; only one study was performed (not placebo-controlled) with IFN- -2a [68].”
MethodCollagenase Versus Placebo in the Treatment of Peyronie’s Disease: A Double-blind Study
Gelbard, M. K., James, K., Riach, P., & Dorey, F. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)35998-0 · Cited by 220
Intralesional Verapamil Injection for the Treatment of Peyronie’s Disease
Levine, L. A., Merrick, P. F., & Lee, R. C. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)35291-6 · Cited by 207 · cited 1×
“The results of the Levine study (intralesion injections of Verapamil/10 mg/biweekly/6-months) shows an improvement of the penile curvature in 42% of the cases and a reduction in plaque volume of 50% in 30% of the patients [55].”
BackgroundPENILE TRAUMA: AN ETIOLOGIC FACTOR IN PEYRONIE'S DISEASE AND ERECTILE DYSFUNCTION
Jarow, J. P., & Lowe, F. C. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64222-8 · Cited by 202 · cited 1×
“The etiology of this fibrotic disease is not widely known, although in recent years pathophysiological knowledge has evolved and new studies propose the penile trauma (micro- or macro-trauma) as cause of the disease [19,20].”
BackgroundTAMOXIFEN VERSUS PLACEBO IN THE TREATMENT OF PEYRONIE’S DISEASE
TELOKEN, C., RHODEN, E. L., GRAZZIOTIN, T. M., DA ROS, C. T., SOGARI, P. R., & SOUTO, C. A. V. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68087-1 · Cited by 201 · cited 1×
“The only randomized, placebo-controlled, double blind trial showed no statistical difference between tamoxifen and placebo [69].”
BackgroundUse of Intralesional Verapamil to Dissolve Peyronie’s Disease Plaque: A Long-Term Single-Blind Study
Rehman, J., Benet, A., & Melman, A. (1998) · Urology · doi:10.1016/s0090-4295(97)00700-0 · Cited by 201 · cited 1×
“Rehman’s research (intralesion injections of Verapamil/1027 mg/weekly/6 months) shows a decrease of the plaque volume in 57% of the cases [56].”
BackgroundPalmieri, A., Imbimbo, C., Longo, N., Fusco, F., Verze, P., Mangiapia, F., Creta, M., & Mirone, V. (2009) · European Urology · doi:10.1016/j.eururo.2009.05.012 · Cited by 189 · cited 1×
“Some placebo-controlled trials revealed no significant improvement in plaque size or penile curvature [109-111].”
BackgroundLong-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases
Jiang, Q., Yin, X., Lill, M. A., Danielson, M. L., Freiser, H., & Huang, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810962106 · Cited by 185 · cited 1×
“It was found that Vitamin E and its metabolites have an antiinflammatory and anti-cyclooxygenase-2 (COX-2) property [74,75].”
BackgroundVouldoukis, I., Lacan, D., Kamate, C., Coste, P., Calenda, A., Mazier, D., Conti, M., & Dugas, B. (2004) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2004.04.023 · Cited by 175
Ha, S. K., Moon, E., & Kim, S. Y. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.08.064 · Cited by 168 · cited 6×
“Vitamin E, in addition to having properties anti-COX-2 property, interacts with hydroxyl radical (hydroxide, the more damaging ROS).”
BackgroundInfluentialAntifibrotic Role of Inducible Nitric Oxide Synthase
Ferrini, M. G., Vernet, D., Magee, T. R., Shahed, A., Qian, A., Rajfer, J., & Gonzalez-Cadavid, N. F. (2002) · Nitric Oxide · doi:10.1006/niox.2001.0421 · Cited by 167 · cited 2×
“mRNA protein, ROS, and the peroxynitrite marker (nitrotyrosine), were all increased in comparison to the normal tunica [51].”
BackgroundPeyronie’s Disease: Prevalence and Association with Cigarette Smoking
La Pera, G., Pescatori, E. S., Calabrese, M., Boffini, A., Colombo, F., Andriani, E., Natali, A., Vaggi, L., Catuogno, C., Giustini, M., et al. (2001) · European Urology · doi:10.1159/000049830 · Cited by 165
El-Sakka, A. I., Hassoba, H. M., Chui, R. M., Bhatnagar, R. S., Dahiya, R., & Lue, T. F. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)68236-3 · Cited by 163 · cited 2×
“The progression of the PD plaque may possibly lead to calcification or ossification in 15-25% of patients [37,48,49].”
BackgroundResultAntioxidant effect of l-carnitine and its short chain esters
Calò, L. A., Pagnin, E., Davis, P. A., Semplicini, A., Nicolai, R., Calvani, M., & Pessina, A. C. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.02.053 · Cited by 161 · cited 1×
“Carnitine stimulates directly the gene and protein expression of haem oxygenase-1 (HO-1) endothelial constitutive nitric oxide synthase (ecNOS) that are known as antioxidant, anti-inflammatory and antiproliferative [89].”
BackgroundFibrin Deposition in Peyronie's Disease Plaque
Somers, K. D., & Dawson, D. M. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65367-9 · Cited by 160
Márquez, N., Sancho, R., Macho, A., Calzado, M. A., Fiebich, B. L., & Muñóz, E. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060673 · Cited by 154
Penile Traction Therapy for Treatment of Peyronie's Disease: A Single-Center Pilot Study
Levine, L. A., Newell, M., & Taylor, F. L. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00814.x · Cited by 150 · cited 2×
“(2008) [114] reported better results on the improvement of curvature; however, the study included a limited sample of patients.”
ResultFibrin Deposition in Peyronie's Disease Plaque
Somers, K. D., & Dawson, D. M. (1997) · The Journal of Urology · doi:10.1097/00005392-199701000-00104 · Cited by 144
Gontero, P., Di Marco, M., Giubilei, G., Bartoletti, R., Pappagallo, G., Tizzani, A., & Mondaini, N. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.01108.x · Cited by 143 · cited 2×
“(2009) [115] in a study of 19 patients with penile curvature with stable PD and treated with penile extender for 6 months, reported only minimal improvements in penile curvature.”
BackgroundAcetyl‐ l ‐carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report
Biagiotti, G., & Cavallini, G. (2001) · BJU International · doi:10.1046/j.1464-410x.2001.02241.x · Cited by 142 · cited 1×
“Although no double-blind placebocontrolled studies have been conducted, Biagiotti & Cavallini in their trial (2001) [90] have shown good efficacy of Acetyl-L-carnitine (1g/oral/twice daily/3 months) in reducing plaque size, penile pain and disease progression.”
BackgroundZargooshi, J. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.01117.x · Cited by 138
FERRINI, M. G., KOVANECZ, I., NOLAZCO, G., RAJFER, J., & GONZALEZ‐CADAVID, N. F. (2006) · BJU International · doi:10.1111/j.1464-410x.2006.05955.x · Cited by 132 · cited 1×
“We think it would be interesting to implement trials concerning the benefits of the use of PDE5 inhibitors in Peyronie’s disease, in fact some recent studies show that these agents may be able to reverse the fibrosis [123,124] also in humans (Tadalafil) [125].”
MethodJordan, G. H. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00651.x · Cited by 125
Treatment of Peyronie’s Disease With Potassium Para-Aminobenzoate (potaba)
Zarafonetis, C. J. D., & Horrax, T. M. (1959) · Journal of Urology · doi:10.1016/s0022-5347(17)66108-1 · Cited by 125 · cited 1×
“In fibroblast cell cultures potaba can reduce the formation of collagen [60].”
BackgroundGreenfield, J. M., Shah, S. J., & Levine, L. A. (2007) · Journal of Urology · doi:10.1016/j.juro.2006.10.065 · Cited by 124 · cited 2×
“[100] have found not statistically significant results.”
BackgroundSafarinejad, M. R. (2004) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901185 · Cited by 120 · cited 1×
“A recent randomized, placebo-controlled trial shows no difference between colchicine and placebo [65] Colchicine is associated with gastrointestinal distress, among these significant diarrhea, and less frequently aplastic anemia.”
BackgroundThe Use of Collagenase in the Treatment of Peyronie’s Disease
Gelbard, M. K., Lindner, A., & Kaufman, J. J. (1985) · Journal of Urology · doi:10.1016/s0022-5347(17)47123-0 · Cited by 118
Wang, Q., Xia, M., Liu, C., Guo, H., Ye, Q., Hu, Y., Zhang, Y., Hou, M., Zhu, H., Ma, J., et al. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.05.017 · Cited by 115 · cited 1×
“Blueberry anthocyanins (flavonoids) inhibit NF- B, iNOS and COX-2 expression [116, 117].”
BackgroundDI STASI, S. M., GIANNANTONI, A., STEPHEN, R. L., CAPELLI, G., GIURIOLI, A., JANNINI, E. A., & VESPASIANI, G. (2004) · Journal of Urology · doi:10.1097/01.ju.0000116450.82816.2c · Cited by 111 · cited 1×
“Three double-blind studies using iontophoresis (two placebocontrolled, and one lidocaine-controlled instead of a placebocontrolled) [100-102] were performed.”
BackgroundCellular and Biochemical Aspects of Normal and Abnormal Wound Healing: An Overview
Diegelmann, R. F. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65364-3 · Cited by 107
Factors Associated in the Aetiology of Peyronie's Disease
CHILTON, C. P., CASTLE, W. M., WESTWOOD, C. A., & PRYOR, J. P. (1982) · British Journal of Urology · doi:10.1111/j.1464-410x.1982.tb13640.x · Cited by 106 · cited 1×
“4-21%) [5, 6], while 10%-40% of patients with PD are affected by Dupuytren’s contractures [7].”
BackgroundWáng, Y., Cao, J., & Zeng, S. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357056299 · Cited by 106 · cited 1×
“Quercetin, kaempferol and isorhamnetin are contained in Ginkgo biloba [118, 119].”
BackgroundA Critical Analysis of Nonsurgical Treatment of Peyronie’s Disease
Hauck, E. W., Thorsten Diemer, A., Schmelz, H. U., & Weidner, W. (2006) · European Urology · doi:10.1016/j.eururo.2006.02.059 · Cited by 105 · cited 8×
“ESWT (Extracorporeal Shockwave Therapy) is another type of "external energy therapies" proposed for the treatment of PD.”
BackgroundInfluentialSun, B., Sun, G., Xiao, J., Chen, R., Wang, X., Wu, Y., Cao, L., Yang, Z., & Sun, X. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23371 · Cited by 102 · cited 1×
“Quercetin and kaempferol are potent inhibitors of hydrogen peroxide (H2O2) production [121].”
BackgroundMARTIN, D. J., BADWAN, K., PARKER, M., & MULHALL, J. P. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64173-0 · Cited by 99 · cited 1×
“measured Verapamil concentrations in the tunica albuginea in patients undergoing surgical treatment (penile prosthesis placement) after application of the verapamil gel to the penile shaft (for a minimum of 12 h) however, the verapamil was not detected in any of the tunica specimens examined [104].”
MethodChung, E., DeYoung, L., & Brock, G. B. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02217.x · Cited by 98 · cited 1×
“We think it would be interesting to implement trials concerning the benefits of the use of PDE5 inhibitors in Peyronie’s disease, in fact some recent studies show that these agents may be able to reverse the fibrosis [123,124] also in humans (Tadalafil) [125].”
Choi, H.-K., Pokharel, Y. R., Lim, S. C., Han, H.-K., Ryu, C. S., Kim, S. K., Kwak, M. K., & Kang, K. W. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.030 · Cited by 98 · cited 12×
“The calcification of the penile plaque may result from osteogenic differentiation of fibroblasts and/or myofibroblasts and may be triggered by TGF-beta-1, chronic inflammation, oxidative stress and other profibrotic factors [49].”
BackgroundInfluentialCollagen Alterations in the Corpus Cavernosum of Men With Sexual Dysfunction
Luangkhot, R., Rutchik, S., Agarwal, V., Puglia, K., Bhargava, G., & Melman, A. (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36630-2 · Cited by 97 · cited 1×
“Some authors reported that men with PD, in their tunica albuginea have more represented type III collagen than type I collagen [46,47].”
BackgroundDeree, J., Martins, J. O., Melbostad, H. S., Loomis, W. H., & Coimbra, R. S. M. (2008) · Clinics · doi:10.1590/s1807-59322008000300006 · Cited by 96 · cited 1×
“PTX is also a phosphodiesterase (PDE) inhibitor that downregulates TNF-alpha release and reduces the transcriptional activity of NF- B [87].”
BackgroundIsolation and Characterization of Collagen in Peyronie’s Disease
Somers, K. D., Sismour, E. N., Wright, G. L., Devine, C. J. J., Gilbert, D., & Horton, C. E. (1989) · The Journal of Urology · doi:10.1016/s0022-5347(17)40920-7 · Cited by 94 · cited 1×
“Some authors reported that men with PD, in their tunica albuginea have more represented type III collagen than type I collagen [46,47].”
BackgroundTreatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy
González-Cadavid, N. F., & Rajfer, J. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.24 · Cited by 90 · cited 1×
“We think it would be interesting to implement trials concerning the benefits of the use of PDE5 inhibitors in Peyronie’s disease, in fact some recent studies show that these agents may be able to reverse the fibrosis [123,124] also in humans (Tadalafil) [125].”
MethodIONTOPHORESIS FOR TREATMENT OF PEYRONIE???S DISEASE
RIEDL, C. R., Plas, E., Engelhardt, P. F., Daha, K., & Pflüger, H. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67981-5 · Cited by 90 · cited 8×
“ESWT (Extracorporeal Shockwave Therapy) is another type of "external energy therapies" proposed for the treatment of PD.”
BackgroundInfluentialVernet, D., Nolazco, G., Cantini, L., Magee, T. R., Qian, A., Rajfer, J., & Gonzalez-Cadavid, N. F. (2005) · Biology of Reproduction · doi:10.1095/biolreprod.105.041038 · Cited by 88
Transdermal Electromotive Multi‐Drug Administration for Peyronie's Disease: Preliminary Results
MONTORSI, F., SALONIA, A., GUAZZONI, G., BARBIERI, L., COLOMBO, R., BRAUSI, M., SCATTONI, V., RIGATTI, P., & PIZZINI, G. (2000) · Journal of Andrology · doi:10.1002/j.1939-4640.2000.tb03279.x · Cited by 87 · cited 1×
“Three double-blind studies using iontophoresis (two placebocontrolled, and one lidocaine-controlled instead of a placebocontrolled) [100-102] were performed.”
BackgroundGene expression in Peyronie's disease
Gonzalez-Cadavid, N. F., Magee, T. R., Ferrini, M., Qian, A., Vernet, D., & Rajfer, J. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900873 · Cited by 84 · cited 1×
“TGFbeta-1, in addition to directly inhibiting collagenase and promoting collagen synthesis, increases ROS levels [50] (Fig.”
BackgroundShindel, A. W., Lin, G., Ning, H., Banie, L., Huang, Y.-C., Liu, G., Lin, C.-S., & Lue, T. F. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01790.x · Cited by 81 · cited 1×
“PTX attenuates TGF-beta-1-stimulated collagen deposition [86].”
Van De Water, L. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65366-7 · Cited by 77
Role of oxidative stress and antioxidants in Peyronie’s disease
Sikka, S. C., & Hellstrom, W. J. G. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900880 · Cited by 77 · cited 1×
“described that the activation of this transcription factor leads to the expression of genes on specific targets: FGF, TGF-beta-1, iNOS, collagen, fibrin [53].”
BackgroundThe association between Peyronie's and Dupuytren's disease
Nugteren, H. M., Nijman, J., de Jong, I., & van Driel, M. V. (2011) · International journal of impotence research · doi:10.1038/ijir.2011.18 · Cited by 73 · cited 1×
“4-21%) [5, 6], while 10%-40% of patients with PD are affected by Dupuytren’s contractures [7].”
BackgroundTRAUMA AS THE CAUSE OF PEYRONIE’S DISEASE: PENILE FRACTURE AS A MODEL OF TRAUMA
ZARGOOSHI, J. (2004) · Journal of Urology · doi:10.1097/01.ju.0000132144.71458.86 · Cited by 69
Intralesional interferon in the treatment of Peyronie's disease: a pilot study
Judge, J. S., & Wisniewski, Z. S. (1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.02849.x · Cited by 67 · cited 1×
“In most of studies interferon alfa-2a (IFN- -2b) was used (intralesional injection) [66, 67]; only one study was performed (not placebo-controlled) with IFN- -2a [68].”
MethodThe Non‐surgical Treatment of Peyronie's Disease
WILLIAMS, G., & GREEN, N. A. (1980) · British Journal of Urology · doi:10.1111/j.1464-410x.1980.tb03067.x · Cited by 67 · cited 1×
“Several Authors in their placebo controlled trials (betamethasone/triamcinolone/intralesional) [97,98] showed no statistical difference between corticosteroids-treated and placebo groups.”
BackgroundRIEDL, C. R., Sternig, P., Gallè, G., Langmann, F., Vcelar, B. A., Vorauer, K., Wagner, A., Katinger, H. W. D., & Pflüger, H. (2005) · European Urology · doi:10.1016/j.eururo.2005.04.011 · Cited by 66 · cited 1×
“Riedl et al, in a randomized placebo-controlled doubleblind prospective clinical study [103], have evaluated the effectiveness of topical gel containing liposomally encapsulated recombinant human Superoxide Dismutase (lrhSOD) scavenger of free oxygen radicals.”
BackgroundImmunologic findings in peyronie's disease: a controlled study
Schiavino, D., Sasso, F., Nucera, E., Alcini, E., Gulino, G., Milani, A., & Patriarca, G. (1997) · Urology · doi:10.1016/s0090-4295(97)00333-6 · Cited by 65 · cited 1×
“Several Authors have suggested an immunological origin of this disease [3, 4].”
BackgroundPathophysiology of Peyronie's disease
Moreland, R. B., & Nehra, A. (2002) · International journal of impotence research · doi:10.1038/sj.ijir.3900875 · Cited by 62
Tunica Albuginea Tissue Analysis After Electromotive Drug Administration
LEVINE, L. A., ESTRADA, C. R., SHOU, W., & COLE, A. (2003) · Journal of Urology · doi:10.1097/01.ju.0000056153.47716.d0 · Cited by 59 · cited 1×
“There has been much discussion about its real effectiveness, although a study of Levine & Estrada (2003) [99] who measured Verapamil concentrations in the tunica albuginea in patients after surgical treatment of PD, showed high concentrations of Verapamil in the tunica albuginea specimens after iontophoresis administr…”
BackgroundProfibrotic Role of Myostatin in Peyronie's Disease
Cantini, L. P., Ferrini, M. G., Vernet, D., Magee, T. R., Qian, A., Gelfand, R. A., Rajfer, J., & Gonzalez-Cadavid, N. F. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00847.x · Cited by 59 · cited 1×
“reported a profibrotic role of Myostatin (a member of the TGF-beta family) in Peyronie's disease [41].”
BackgroundThe Genetic and Bacteriological Aspects of Peyronie's Disease
Ralph, D. J., Schwartz, G., Moore, W., Pryor, J. P., Ebringer, A., & Bottazzo, G. F. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65362-x · Cited by 58 · cited 2×
“found a significant association between Peyronie's disease and HLA-B27 [8].”
BackgroundNachtsheim, D. A., & Rearden, A. (1996) · The Journal of Urology · doi:10.1097/00005392-199610000-00021 · Cited by 55
Nachtsheim, D. A., & Rearden, A. (1996) · PubMed · Cited by 54
Peyronie’s Disease: Experience of Local Treatment with Orgotein
Gustafson, H., Johansson, B., & Edsmyr, F. (1981) · European Urology · doi:10.1159/000473262 · Cited by 54 · cited 1×
“Several studies have been performed using Orgotein (intralesional injection) [93,94] for the treatment of PD obtaining good results on pain, penile curvature and plaque size, however, no placebocontrolled study has been published.”
BASIC FIBROBLAST GROWTH FACTOR EXPRESSION IN PEYRONIE'S DISEASE
MULHALL, J. P., THOM, J., LUBRANO, T., & SHANKEY, T. V. (2001) · Journal of Urology · doi:10.1097/00005392-200102000-00016 · Cited by 53 · cited 2×
“In Peyronie's disease production of FGF by the plaque derived myofibroblasts resulted in significantly higher [44].”
BackgroundPeyronie’s disease associated with increase in plasminogen activator inhibitor in fibrotic plaque
Davila, H. H., Magee, T. R., Zuniga, F. I., Rajfer, J., & González-Cadavid, N. F. (2005) · Urology · doi:10.1016/j.urology.2005.01.010 · Cited by 52 · cited 1×
“TGF-beta-1, PDGF and plasminogen activator inhibitor-1 (PAI-1: profibrotic protein) are overexpressed in PD plaques [45].”
Background[Betamethasone versus placebo in Peyronie's disease].
Cipollone, G., Nicolai, M., Mastroprimiano, G., Iantorno, R., Longeri, D., & Tenaglia, R. M. (1998) · PubMed · Cited by 51
Extracorporeal shockwave therapy for Peyronie's disease does not correct penile deformity
Strebel, R., Suter, S., Sautter, T., & Hauri, D. (2004) · International journal of impotence research · doi:10.1038/sj.ijir.3901192 · Cited by 50 · cited 1×
“Two European studies with a very detailed evaluation of symptoms after treatment with ESWT revealed no significant changes [107, 108].”
BackgroundGentile, V., Modesti, A., Pera, G. L., Vasaturo, F., Modica, A., Prigiotti, G., Silverio, F. D., & Scarpa, S. (1996) · PubMed · Cited by 45
A sensitive method for the detection and quantification of ginkgo flavonols from plasma
Zhao, Y., Wang, L., Bao, Y., & Li, C. (2007) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2907 · Cited by 42 · cited 1×
“Quercetin, kaempferol and isorhamnetin are contained in Ginkgo biloba [118, 119].”
BackgroundThe Ultrasonic Treatment of Peyronie’s Disease
Frank, I. N., & Scott, W. W. (1971) · The Journal of Urology · doi:10.1016/s0022-5347(17)61427-7 · Cited by 40 · cited 1×
“Some authors have suggested that ESWT (as the ultrasonic treatment), by causing repeated trauma to the area of plaque, can lead to the creation of contralateral scarring of the penis resulting in “false” straightening [105, 106].”
BackgroundReview of current nonsurgical management of Peyronie's disease
Levine, L. A. (2003) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901084 · Cited by 36 · cited 1×
“Some authors have suggested that ESWT (as the ultrasonic treatment), by causing repeated trauma to the area of plaque, can lead to the creation of contralateral scarring of the penis resulting in “false” straightening [105, 106].”
BackgroundSkarpańska-Stejnborn, A., Pilaczyńska-Szczȩśniak, Ł., Basta, P., Deskur-Śmielecka, E., Woitas-Ślubowska, D., & Adach, Z. (2011) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.21.2.124 · Cited by 34 · cited 1×
“It is currently marketed a superoxide dismutase of plant origin (cantaloupe melon) [95,96], it would be interesting to perform placebo-controlled trials with this new preparation.”
BackgroundNon-surgical therapy of Peyronie's disease
Taylor, F. L., & Levine, L. A. (2008) · Asian Journal of Andrology · doi:10.1111/j.1745-7262.2008.00351.x · Cited by 33 · cited 1×
“In conclusion the following factors represent a limitation on the use of potaba: low effectiveness against penile curvature and pain, high daily dosage required (12 grams/daily) and the possible related side effects [62-64], high cost and the unavailability in some countries.”
BackgroundNitric Oxide Induces Oxidative Stress and Mediates Cytotoxicity to Human Cavernosal Cells in Culture
Rajasekaran, M. R., Hellstrom, W. J. G., & Sikka, S. C. (2001) · Journal of Andrology · doi:10.1002/j.1939-4640.2001.tb02150.x · Cited by 32
Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie's disease
Bivalacqua, T. J., Champion, H. C., & Hellstrom, W. J. G. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900872 · Cited by 31 · cited 3×
“When concentrations of NO increase in course of inflammation, nitric oxide radical competes with superoxide dismutase (SOD) and leads to production of peroxynitrite (ONOO-) a highly toxic and pro-fibrotic compound that induces cytotoxic effects on cavernosal muscle by: lipid peroxidation, DNA fragmentation, damage and…”
BackgroundOutcome analysis for conservative management of Peyronie's disease
Hashimoto, K., Hisasue, S., Kato, R., Kobayashi, K., Shimizu, T., & Tsukamoto, T. (2006) · International Journal of Urology · doi:10.1111/j.1442-2042.2006.01270.x · Cited by 30 · cited 2×
“(2006) [77], in a placebocontrolled study showed no higher effect of vitamin E compared to placebo.”
BackgroundSong, J., Cho, J., Hwang, S.-J., Cho, C. G., Park, S.-W., & Chae, S. W. (2008) · Acta Oto-Laryngologica · doi:10.1080/00016480801947082 · Cited by 30 · cited 2×
“In particular CAPE specifically inhibits: IL-2 gene transcription and IL-2 synthesis in stimulated T-cells [79]; TNF-alpha expression and interleukin IL-8 production [80].”
BackgroundOrgotein in the treatment of plastic induration of the penis (Peyronie's disease).
Primus, G. (1993) · PubMed · Cited by 28
Costa, W. S., Rebello, S. B., Cardoso, L. E. M., Cavalcanti, A. G., & Sampaio, F. J. B. (2009) · BJU International · doi:10.1111/j.1464-410x.2008.08023.x · Cited by 27 · cited 1×
“This seems to suggest that, in patients with PD, the noxa (phenotypic expression) is widespread within the entire tunica albuginea of the corpora cavernosa [9,10].”
BackgroundPolat, Ö., Gül, O., Özbey, I., Özdikici, M., & Bayraktar, Y. (1997) · International Urology and Nephrology · doi:10.1007/bf02551115 · Cited by 25 · cited 1×
“In most of studies interferon alfa-2a (IFN- -2b) was used (intralesional injection) [66, 67]; only one study was performed (not placebo-controlled) with IFN- -2a [68].”
MethodPaulis, G., D’Ascenzo, R., Nupieri, P., De Giorgio, G., Orsolini, G., Brancato, T., & Alvaro, R. (2012) · International Journal of Andrology · doi:10.1111/j.1365-2605.2011.01219.x · Cited by 24 · cited 3×
“More recently, our research that has compared outcomes in different therapeutic groups of patients with PD (patients treated with verapamil + flavonoids + topical diclofenac + vitamin E; patients treated with verapamil + flavonoids + topical diclofenac) showed more significant improvements in the groups treated with v…”
BackgroundInfluentialSelf-citationSignificant alterations of serum cytokine levels in patients with Peyronie's disease
Zimmermann, R. P., Feil, G., Bock, C., Hoeltl, L., & Stenzl, A. (2008) · International braz j urol · doi:10.1590/s1677-55382008000400008 · Cited by 23 · cited 1×
“TGFbeta-1 induces the biosynthesis of collagen and leads to the formation of plaque; this is demonstrated both in animal models than in human [37,38].”
ResultRadiation Increases Fibrogenic Cytokine Expression by Peyronie’s Disease Fibroblasts
MULHALL, J. P., BRANCH, J., LUBRANO, T., & SHANKEY, T. V. (2003) · Journal of Urology · doi:10.1097/01.ju.0000070860.78370.08 · Cited by 22 · cited 1×
“evaluated the effect of radiation on fibrogenic cytokine production in cells cultured from PD plaque tissue; the study has shown that radiation therapy may increase the production of fibrogenic cytokines and promote the fibrotic process [112].”
BackgroundRoy, J., & Carrier, S. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00918.x · Cited by 21 · cited 1×
“In conclusion the following factors represent a limitation on the use of potaba: low effectiveness against penile curvature and pain, high daily dosage required (12 grams/daily) and the possible related side effects [62-64], high cost and the unavailability in some countries.”
BackgroundCarlo, M. D., Cole, A. A., Hart, S. G. E., & Levine, L. A. (2009) · The Journal of Urology · doi:10.1016/s0022-5347(09)60794-1 · Cited by 18
[Clinical evaluation of the use of propoleum in Peyronie's disease].
Lemourt Oliva, M., Filgueiras López, E., Rodríguez Barroso, A., Oramas, E. G., & Ramírez, R. B. (1998) · PubMed · Cited by 15
[Clinical effects of verapamil in the treatment of Peyronie's disease].
Arena, F., Peracchia, G., Di Stefano, C., Passari, A., Larosa, M., & Cortellini, P. (1995) · PubMed · Cited by 11
[Propoleum and Peyronie's disease].
Oliva, M. L., Barroso, A. R., Guillen, M., Guerrero, C. V., Cutiño, M. N., & Monzón, A. F. P. (2003) · PubMed · Cited by 10
[Study of propoleum dosage in Peyronie's disease].
Oliva, M. L., Barroso, A. R., Ramírez, R. B., Oramas, E. G., & Castillo, F. M. (2003) · PubMed · Cited by 8
Oliva, M. L., Valdés, R. F., Ramírez, R. B., Santana, J. L., Oramas, E. G., & Merino, A. (2005) · Archivos Españoles de Urología · doi:10.4321/s0004-06142005000900010 · Cited by 8
Tratamiento y manejo actual de la fase aguda de la enfermedad de Peyronie
Vanni, A. J., & Bennett, N. (2009) · Archivos Españoles de Urología · doi:10.4321/s0004-06142009000800002 · Cited by 6
Hatzichristodoulou, G., Meisner, C., Stenzl, A., & Lahme, S. (2007) · European Urology Supplements · doi:10.1016/s1569-9056(07)60542-9 · Cited by 6
Cited by
d'Agostino, M. C., Craig, K., Tibalt, E., & Respizzi, S. (2015) · International Journal of Surgery · doi:10.1016/j.ijsu.2015.11.030 · Cited by 287
Adipose Tissue Dysfunction and Obesity-Related Male Hypogonadism
Genchi, V. A., Rossi, E., Lauriola, C., D’Oria, R., Palma, G., Borrelli, A., Caccioppoli, C., Giorgino, F., & Cignarelli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158194 · Cited by 175
Lipshultz, L. I., Goldstein, I., Seftel, A. D., Kaufman, G. J., Smith, T. M., Tursi, J. P., & Burnett, A. L. (2015) · BJU International · doi:10.1111/bju.13096 · Cited by 120
Paulis, G., Brancato, T., D'Ascenzo, R., De Giorgio, G., Nupieri, P., Orsolini, G., & Alvaro, R. (2013) · Andrology · doi:10.1111/j.2047-2927.2012.00007.x · Cited by 67
“…many recent studies have demonstrated the efficacy of several substances with anti-oxidative activity (propolis, carnitine, pentoxifylline, coenzyme Q10, blueberry flavonoids etc.) in the treatment of PD (Cavallini et al., 2002; Safarinejad, 2010b; Safarinejad et al., 2010a; Paulis et al., 2012).”
BackgroundSelf-citationNonsurgical management of Peyronie’s disease
Tsambarlis, P., & Levine, L. A. (2019) · Nature Reviews Urology · doi:10.1038/s41585-018-0117-7 · Cited by 64
Metadata
- Authors
- Paulis, G., & Brancato, T.
- Affiliations
- Ospedale Regina Apostolorum (IT)
- ORCID
- Paulis, Gianni
- Venue
- Inflammation & Allergy - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-02-01
- Volume
- 11
- Issue
- 1
- Pages
- 48-57
- ISSN
- 1871-5281 (ISSN-L)
- OpenAlex
- W2025237264
- Cited by
- 60
- References
- 103
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 6 · 2015: 9 · 2014: 3 · 2013: 5 · 2012: 2
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Inflammation & Allergy - Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Health Sciences › Medicine › Urology › Urological Disorders and Treatments
- Keywords
- Peyronie's disease, tunica albuginea fibrosis, penile curvature, oxidative stress, reactive oxygen species, NF-κB, inducible nitric oxide synthase, nitric oxide, peroxynitrite, myofibroblast proliferation, collagen deposition, penile trauma, extracorporeal shock wave therapy, verapamil, collagenase, hyaluronidase, pentoxifylline, iontophoresis, corticosteroids, interferon, tamoxifen
- MeSH terms
- Animals, Colchicine, Humans, Inflammation, Male, Penile Induration, Penis, Verapamil, Vitamin E, Treatment Outcome, Reactive Oxygen Species, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.